References

Ahmed, S., Bradshaw, A.-D., Gera, S., Dewan, M., & Xu, R. (2017). The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance. *Journal of Clinical Medicine*, *6*(1), 5. https://doi.org/10.3390/jcm6010005

American Cancer Society. (2024). *Pancreatic Cancer Risk Factors*. Www.cancer.org. https://www.cancer.org/cancer/types/pancreatic-cancer/causes-risks-prevention/risk-factors.html

Barbiero, M., Cirillo, L., Sapthaswaran Veerapathiran, Coates, C., Ruffilli, C., & Pines, J. (2022). Cell cycle-dependent binding between Cyclin B1 and Cdk1 revealed by time-resolved fluorescence correlation spectroscopy. *Open Biology*, *12*(6). https://doi.org/10.1098/rsob.220057

Barnum, K. J., & O'Connell, M. J. (2014). Cell Cycle Regulation by Checkpoints. *Methods in Molecular Biology*, *1170*, 29–40. https://doi.org/10.1007/978-1-4939-0888-2_2

Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., Yavas, A., Lecomte, N., Erakky, A., Varghese, A. M., Zhang, A., Kendall, J., Ghiban, E., Chorbadjiev, L., Wu, J., & Dimitrova, N. (2022). Ordered and deterministic cancer genome evolution after p53 loss. *Nature*, *608*(7924), 795–802. https://doi.org/10.1038/s41586-022-05082-5

Beishline, K., & Azizkhan-Clifford, J. (2014). Interplay Between the Cell Cycle and Double-Strand Break Response in Mammalian Cells. *Methods in Molecular Biology*, 41–59. https://doi.org/10.1007/978-1-4939-0888-2_3

Bogumil, D., Stram, D., Preston, D. L., Pandol, S. J., Wu, A. H., McKean-Cowdin, R., Conti, D. V., & Veronica Wendy Setiawan. (2023). Excess pancreatic cancer risk due to smoking and modifying effect of quitting smoking: The Multiethnic Cohort Study. *Cancer Causes & Control*, *35*(3), 541–548. https://doi.org/10.1007/s10552-023-01811-x

Bretones, G., Delgado, M. D., & León, J. (2015). Myc and cell cycle control. *Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms*, *1849*(5), 506–516. https://doi.org/10.1016/j.bbagrm.2014.03.013

Chang, H. H. Y., Pannunzio, N. R., Adachi, N., & Lieber, M. R. (2017). Non-homologous DNA end joining and alternative pathways to double-strand break repair. *Nature Reviews Molecular Cell Biology*, *18*(8), 495–506. https://doi.org/10.1038/nrm.2017.48

Dai, Y., & Grant, S. (2010). New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network. *Clinical Cancer Research*, *16*(2), 376–383. https://doi.org/10.1158/1078-0432.ccr-09-1029

Fang, Y.-T., Yang, W.-W., Niu, Y.-R., & Sun, Y.-K. (2023). Recent advances in targeted therapy for pancreatic adenocarcinoma. *World Journal of Gastrointestinal Oncology*, *15*(4), 571–595. https://doi.org/10.4251/wjgo.v15.i4.571

Ferlay, J., Ervik, M., Lam, F., Laversanne, M., Colombet, M., Mery, L., Piñeros, M., Znaor, A., Soerjomataram, I., & Bray, F. (2024). *Global Cancer Observatory: Cancer Today*. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today

Guiducci, G., & Stojic, L. (2021). Long Noncoding RNAs at the Crossroads of Cell Cycle and Genome Integrity. *Trends in Genetics*, *37*(6), 528–546. https://doi.org/10.1016/j.tig.2021.01.006

Hanahan, D., & Weinberg, Robert A. (2011). Hallmarks of cancer: the next Generation. *Cell*, *144*(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013

Haydock, M. M., Sigdel, S., & Pacioles, T. (2018). Gemcitabine-induced skin necrosis. *SAGE Open Medical Case Reports*, *6*, 2050313X1880926. https://doi.org/10.1177/2050313x18809268

Hudson, D. F., Amor, D. J., Boys, A., Butler, K., Williams, L., Zhang, T., & Kalitsis, P. (2016). Loss of RMI2 Increases Genome Instability and Causes a Bloom-Like Syndrome. *PLOS Genetics*, *12*(12), e1006483. https://doi.org/10.1371/journal.pgen.1006483

Jackman, M., Marcozzi, C., Barbiero, M., Pardo, M., Yu, L., Tyson, A. L., Choudhary, J. S., & Pines, J. (2020). Cyclin B1-Cdk1 facilitates MAD1 release from the nuclear pore to ensure a robust spindle checkpoint. *Journal of Cell Biology*, *219*(6). https://doi.org/10.1083/jcb.201907082

Jain, A., & Bhardwaj, V. (2021). Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. *World Journal of Gastroenterology*, *27*(39), 6527–6550. https://doi.org/10.3748/wjg.v27.i39.6527

Lai, E., Ziranu, P., Spanu, D., Dubois, M., Pretta, A., Tolu, S., Camera, S., Liscia, N., Mariani, S., Persano, M., Migliari, M., Donisi, C., Demurtas, L., Pusceddu, V., Puzzoni, M., & Scartozzi, M. (2021). BRCA-mutant pancreatic ductal adenocarcinoma. *British Journal of Cancer*, *125*(10), 1321–1332. https://doi.org/10.1038/s41416-021-01469-9

Lambert, A., Gavoille, C., & Conroy, T. (2017). Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. *Therapeutic Advances in Gastroenterology*, *10*(8), 631–645. https://doi.org/10.1177/1756283x17713879

Lee, K. Y., & Dutta, A. (2021). Chk1 promotes non-homologous end joining in G1 through direct phosphorylation of ASF1A. *Cell Reports*, *34*(4), 108680. https://doi.org/10.1016/j.celrep.2020.108680

Li, Y., He, X., Zhang, X., Xu, Y., Chen, W., Liu, X., & Xu, X. (2021). RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. *Clinical and Experimental Medicine.* https://doi.org/10.1007/s10238-021-00742-8

Liben, M., & Warren, A. (2023). DELAYED STEROID THERAPY IN GEMCITABINE-INDUCED PNEUMONITIS. *CHEST*, *164*(4), A3339. https://doi.org/10.1016/j.chest.2023.07.2179

Lin, Y. C., & Prasanth, S. G. (2021). Replication initiation: Implications in genome integrity. *DNA repair*, *103*, 103131. https://doi.org/10.1016/j.dnarep.2021.103131

Liu, J., Nie, S., Gao, M., Jiang, Y., Wan, Y., Ma, X., Zhou, S., & Cheng, W. (2019). Identification of EPHX2 and RMI2 as two novel key genes in cervical squamous cell carcinoma by an integrated

bioinformatic analysis. *Journal of cellular physiology*, *234*(11), 21260–21273. https://doi.org/10.1002/jcp.28731

Liu, Y., & West, S. C. (2008). More complexity to the Bloom's syndrome complex. *Genes & development, 22*(20), 2737–2742. https://doi.org/10.1101/gad.1732808

Lu, S., Ahmed, T., Du, P., & Wang, Y. (2017). Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. *International Journal of Molecular Sciences, 18*(6), 1201. https://doi.org/10.3390/ijms18061201

Luo, J. (2021). KRAS mutation in pancreatic cancer. *Seminars in Oncology*, *48*(1), 10–18. https://doi.org/10.1053/j.seminoncol.2021.02.003

Luo, W., Wang, D., Chen, H., Ye, L., Qiu, J., Liu, Y., Wang, R., Weng, G., Liu, T., Su, D., Tao, J., Ding, C., Li, Y., & Zhang, T. (2023). Epidemiology of pancreatic cancer: New version, new vision. *Chinese Journal of Cancer Research*, *35*(5), 438–450. https://doi.org/10.21147/j.issn.1000-9604.2023.05.03

Montalto, F. I., & De Amicis, F. (2020). Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. *Cells*, *9*(12), 2648. https://doi.org/10.3390/cells9122648

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., Campos, D., Lim, R., Ding, K., Clark, G., Voskoglou-Nomikos, T., Ptasynski, M., & Parulekar, W. (2007). Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. *Journal of Clinical Oncology*, *25*(15), 1960–1966. https://doi.org/10.1200/jco.2006.07.9525

Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., Frame, M. C., Evans, T. R. J., & Sansom, O. J. (2010). Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer.

Proceedings of the National Academy of Sciences of the United States of America, *107*(1), 246–251. https://doi.org/10.1073/pnas.0908428107

Mukund, A., Afridi, M. A., Karolak, A., Park, M. A., Permuth, J. B., & Rasool, G. (2024). Pancreatic Ductal Adenocarcinoma (PDAC): A Review of Recent Advancements Enabled by Artificial Intelligence. *Cancers*, *16*(12), 2240. https://doi.org/10.3390/cancers16122240

Murakawa, M., Kawahara, S., Takahashi, D., Yuto Kamioka, Yamamoto, N., Kobayashi, S., Ueno, M., Morimoto, M., Sho Sawazaki, Takahashi, H., Takashi Ohshima, Yukawa, N., Rino, Y., & Morinaga, S. (2023). Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection. *World Journal of Surgical Oncology*, *21*(1). https://doi.org/10.1186/s12957-023-03141-3

National Cancer Institute. (2011). *https://www.cancer.gov/publications/dictionaries/cancer-terms/def/genomic-instability*. Www.cancer.gov. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/genomic-instability

National Cancer Institute. (2023). *Cancer of the Pancreas - Cancer Stat Facts*. SEER; National Cancer Institute. https://seer.cancer.gov/statfacts/html/pancreas.html

Nguyen, D.-D., Kim, E. Y., Sang, P. B., & Chai, W. (2020). Roles of OB-Fold Proteins in Replication Stress. *Frontiers in Cell and Developmental Biology*, *8*. https://doi.org/10.3389/fcell.2020.574466

Patil, M., Pabla, N., & Dong, Z. (2013). Checkpoint kinase 1 in DNA damage response and cell cycle regulation. *Cellular and Molecular Life Sciences*, *70*(21), 4009–4021. https://doi.org/10.1007/s00018-013-1307-3

Pellarin, I., Dall'Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025). Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. *Signal Transduction and Targeted Therapy*, *10*(1). https://doi.org/10.1038/s41392-024-02080-z

Petsalaki, E., & Zachos, G. (2020). DNA damage response proteins regulating mitotic cell division: double agents preserving genome stability. *The FEBS Journal*, *287*(9), 1700–1721. https://doi.org/10.1111/febs.15240

Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021). The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. *Frontiers in Oncology*, *11*. https://doi.org/10.3389/fonc.2021.688377

Prabahar, A., Zamora, R., Barclay, D., Yin, J., Ramamoorthy, M., Bagheri, A., Johnson, S. A., Badylak, S., Yoram Vodovotz, & Jiang, P. (2024). Unraveling the complex relationship between mRNA and protein abundances: a machine learning-based approach for imputing protein levels from RNA-seq data. *NAR Genomics and Bioinformatics,* *6*(1). https://doi.org/10.1093/nargab/lqae019

Ren, S., Qian, L.-C., Cao, Y.-Y., Daniels, M. J., Song, L.-N., Tian, Y., & Wang, Z.-Q. (2024). Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma. *World Journal of Gastrointestinal Oncology*, *16*(4), 1256–1267. https://doi.org/10.4251/wjgo.v16.i4.1256

Reyngold, M., O'Reilly, E. M., Varghese, A. M., Fiasconaro, M., Zinovoy, M., Romesser, P. B., Wu, A., Hajj, C., Cuaron, J. J., Tuli, R., Hilal, L., Khalil, D., Park, W., Yorke, E. D., Zhang, Z., Yu, K. H., & Crane, C. H. (2021). Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. *JAMA Oncology*, *7*(5), 735. https://doi.org/10.1001/jamaoncol.2021.0057

RMI2 RecQ mediated genome instability 2 [Homo sapiens (human)] - Gene - NCBI. (2025). Nih.gov. https://www.ncbi.nlm.nih.gov/gene/116028

Sarantis, P., Koustas, E., Papadimitropoulou, A., Papavassiliou, A. G., & Karamouzis, M. V. (2020). Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy. *World Journal of Gastrointestinal Oncology*, *12*(2), 173–181. https://doi.org/10.4251/wjgo.v12.i2.173

Seshacharyulu, P., Baine, M. J., Souchek, J. J., Menning, M., Kaur, S., Yan, Y., Ouellette, M. M., Jain, M., Lin, C., & Batra, S. K. (2017). Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochimica et biophysica acta. *Reviews on cancer, 1868*(1), 69–92. https://doi.org/10.1016/j.bbcan.2017.02.003

Sharma, A., & Chari, S. T. (2018). Pancreatic cancer and diabetes mellitus. *Current treatment options in gastroenterology*, *16*, 466-478.Chicago

Singh, T. R., Ali, A. M., Busygina, V., Raynard, S., Fan, Q., Du, C. ., Andreassen, P. R., Sung, P., & Meetei, A. R. (2008). BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. *Genes & Development*, *22*(20), 2856–2868. https://doi.org/10.1101/gad.1725108

Sun, G., Wu, Y., Li, J., Yang, M., Xu, H., Li, Y., Tong, P., Shao, R., Liu, Y., & Kong, X. (2025). Quercetin liposomes conjugated with hyaluronidase: An efficient drug delivery system to block pancreatic cancer. *Journal of Controlled Release*, *382*, 113642. https://doi.org/10.1016/j.jconrel.2025.113642

Tsuda, M., Fukuda, A., Kawai, M., Araki, O., & Seno, H. (2021). The role of the SWI/SNF chromatin remodeling complex in pancreatic ductal adenocarcinoma. *Cancer science*, *112*(2), 490–497.

Vermeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. *Cell Proliferation*, *36*(3), 131–149. https://doi.org/10.1046/j.1365-2184.2003.00266.x

Wang, H., Mannava, S., Grachtchouk, V., Zhuang, D., Soengas, M. S., Gudkov, A. V., Prochownik, E. V., & Nikiforov, M. A. (2008). c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. *Oncogene*, *27*(13), 1905–1915. https://doi.org/10.1038/sj.onc.1210823

Wijnen, R., Pecoraro, C., Carbone, D., Fiuji, H., Avan, A., Peters, G. J., Giovannetti, E., & Diana, P. (2021). Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against

Pancreatic Ductal Adenocarcinoma (PDAC). *Cancers*, *13*(17), 4389. https://doi.org/10.3390/cancers13174389

Yang, V. W. (2012). The Cell Cycle. *Physiology of the Gastrointestinal Tract*, *1*, 451–471. https://doi.org/10.1016/b978-0-12-382026-6.00015-4

Yasuda, S., Nagai, M., Nakamura, K., Matsuo, Y., & Sho, M. (2025). Role of radiotherapy in surgical approaches to pancreatic cancer treatment: A narrative review. *Annals of Gastroenterological Surgery*, *9*(3), 418–428. https://doi.org/10.1002/ags3.70012

Zhang, W., Liu, B., Wu, W., Li, L., Broom, B. M., Basourakos, S. P., Korentzelos, D., Luan, Y., Wang, J., Yang, G., Park, S., Azad, A. K., Cao, X., Kim, J., Corn, P. G., Logothetis, C. J., Aparicio, A. M., Chinnaiyan, A. M., Navone, N., Troncoso, P., … Thompson, T. C. (2018). Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, *24*(3), 696–707. https://doi.org/10.1158/1078-0432.CCR-17-1872

Zhan, W., Liu, Y., Gao, Y., Gong, R., Wang, W., Zhang, R., Wu, Y., Kang, T., & Wei, D. (2020). RMI2 plays crucial roles in growth and metastasis of lung cancer. *Signal Transduction and Targeted Therapy*, *5*(1). https://doi.org/10.1038/s41392-020-00295-4

Zhang, L., Hao, C., Han, B., Zeng, G., Han, L., Cao, C., Liu, H., Zhong, Z., Zhao, X., Wang, J., & Zhang, Q. (2022). RMI2 is a novel prognostic and predictive biomarker for breast cancer. *Cancer Medicine*, *12*(7), 8331–8350. https://doi.org/10.1002/cam4.5533